FDA Approves Topical Ruxolitinib for Non-Segmental Vitiligo

Non-segmental vitiligo is the most common and can appear at any age and affect different locations, and is characterized by being triggered by, among other things, trauma, which is known as Koebner phenomenon.
The approval was based on the results of 674 patients with non-segmental vitiligo aged 12 years or older. At 24 weeks, about 30% of patients on treatment, applied twice daily, achieved at least a 75% improvement in the facial vitiligo area score index.

To read the full article visit: https://medicinaysaludpublica.com/noticias/dermatologia/fda-aprueba-ruxolitinib-topico-para-el-vitiligo-no-segmentario/14898

and https://www.medscape.com/viewarticle/977464